摘要
近四十年来,原发性胆汁性胆管炎(PBC)患者得益于熊去氧胆酸(UDCA)的广泛应用,治疗应答率和生存率逐年增加,预后得到普遍改善。然而部分患者对UDCA治疗应答不佳,长期结局较差。因此,根据患者的血清学和病理学特点,准确诊断、评估并进行风险分层对PBC的治疗十分重要。本文就PBC的诊治进展作一概述。
In the past 40 years,patients with primary biliary cholangitis（ PBC） have benefited from the extensive use of ursodeoxycholic acid（ UDCA）,resulting in increase of response rate and survival rate. The prognosis of PBC patients was significantly improved. However, some patients responded poorly to UDCA and with poor long-term outcome.Therefore,accurate diagnosis,evaluation and risk stratification based on serological and pathological characteristics of the patients are very important for the treatment of PBC. This article summarized the progress in diagnosis and treatment of PBC.
作者
施漪雯
尤红
SHI Yiwen, YOU Hong.(Liver Disease Research Center, Beijing Friendship Hospital, Capital Medical University; Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis; National Clinical Research Center for Digestive Diseases, Beijing （100050）)
出处
《胃肠病学》
2018年第5期266-270,共5页
Chinese Journal of Gastroenterology
关键词
原发性胆汁性胆管炎
熊去氧胆酸
诊断
治疗
Primary Biliary Cholangitis
Ursodeoxycholic Acid
Diagnosis
Therapy
